a series of 150 patients with hereditary spherocytosis grouped according to the clinical phenotype and the defective protein, with the final aim to find the combination of tests associated with the highest diagnostic power, even in the mildest cases.
Results: EMA-binding displayed 93% sensitivity and 98% specificity: sensitivity was independent of the type and amount of molecular defect and of clinical phenotype. A comparable sensitivity was shown by AGLT (95%) and Pink test (91%). The sensitivity of NaCl osmotic fragility tests, commonly considered the gold standard for diagnosis of hereditary spherocytosis, was 68% on fresh and 81% on incubated blood, and further decreased in compensated cases (53% and 64%). The combination of EMA and AGLT enabled to identify the totality of patients. EMA-binding test shows the greater disease specificity.
Conclusions:
Each individual test fails to diagnose a portion of cases. The association of EMAbinding and AGLT allowed to identify all the hereditary spherocytosis patients of this series and therefore represents at present an effective diagnostic tool for hereditary spherocytosis also in mild/compensated cases.
INTRODUCTION

Hereditary spherocytosis (HS) is the most common congenital hemolytic anemia in Caucasians,
affecting approximately 1 in 1000-2000 individuals.
1,2 The molecular defect is highly heterogeneous involving the genes encoding for spectrin, ankyrin, band 3 and protein 4.2, 3 and the degree of hemolysis varies widely, from fully compensated to transfusion-dependent anemia.
The typical laboratory hallmark of HS, although not specific, is the presence of spherocytes on peripheral blood smear, which are detectable in 97% of patients. 4 However, spherocytes may be very few in several patients 4,5 requiring skilled operators to be detected; moreover, the microscopic examination of red cells is increasingly omitted in an era of laboratory automation. The laboratory diagnosis of HS therefore commonly relies on tests that exploit the surface area-to-volume ratio, typically reduced in spherical-shaped erythrocytes, in particular the red cell osmotic fragility (OF) tests at various sodium chloride (NaCl) concentrations on fresh and incubated blood, 6 and assays that measure the extent or the rate of lysis of red cells suspended in buffered glycerol solutions, i.e.
Glycerol Lysis (GLT), 7 Acidified Glycerol Lysis (AGLT) 8 and Pink test. 9 However, these tests miss a variable portion of HS cases, particularly the mildest ones, 6,10-12 and do not differentiate HS from secondary spherocytosis associated with other conditions, mainly autoimmune hemolytic anemias. [13] [14] [15] More recently, the cryohemolysis test, 16, 17 based on the observation that HS red cells are particularly susceptible to cooling at 0° C in hypertonic conditions, and the flow cytometric analysis of eosin-5'-maleimide-labelled intact red blood cells (EMA-binding test) 18 have been proposed as new methods of identifying HS. 19 The latter in particular has been proven to be a sensitive and specific diagnostic tool for HS 12, 18, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] directly targeting the structural lesion of this disease, since the fluorescent probe eosin-5'-maleimide interacts with the protein band 3 complex.
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The performance of the available direct or indirect diagnostic tests has been mostly evaluated individually and on limited number of cases: in particular, sensitivity is greatly variable, and each method fails to identify several HS patients. 4, 6, 12 In this study, we compared the performances of EMA-binding, NaCl OF on fresh and incubated blood, GLT, AGLT and Pink tests on a series of 150 HS patients grouped according to the clinical phenotype and the molecular lesion, with the final aim to find the combination of tests associated with the highest diagnostic power towards HS, included the mildest cases which are of more difficult diagnosis. females and Hb>10 and <13.5 g/dL for males) and compensated (Hb>11.5 g/dL for females and >13.5 g/dL for males).
4
DESIGN AND METHODS
Subjects
All patients underwent SDS-PAGE analysis of the red cell membrane proteins and were divided into the following groups: deficiency of band 3, spectrin, ankyrin or combined spectrin/ankyrin, and no detectable defect. In order to decrease intra-assay variation, patients' samples were compared with those of six normal controls. Results were expressed as the percentage of fluorescence reduction of the patient compared to the mean fluorescence of the six normal controls as proposed by Girodon et al.
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Receiver Operating Characteristic (ROC) curve based on logistic regression analysis was used to determine the optimum cut-off between HS and normal individuals. According to the ROC curve analysis, the optimum decrease in fluorescence to separate normal subjects form HS patients was 11%. In these conditions test specificity computed on 575 healthy subjects was 98 %.
Red cell ghosts were prepared within 24 hours of blood collection using the method of Dodge et al. 33 with slight modifications. 4 Red cell membrane proteins were analyzed within 15 days of ghosts preparation by SDS-PAGE using a 4% to 12% gradient of acrylamide according to Fairbanks et al. 34 and the discontinuous buffer system of Laemmli 35 with an acrylamide linear gradient from 6%
to 14%, as previously described. 4 Activities of enzymes of the glycolytic and pentose phosphate pathways were assayed using the methods described by Beutler. Table 1 shows the hematologic and biochemical data of HS patients grouped according to whether they had not been splenectomized or had been splenectomized before the time of the study, and according to the clinical phenotype (in non-splenectomized only). The majority of nonsplenectomized subjects displayed mild to compensated hemolysis; 18% had very few spherocytes (<3%). The most common protein abnormalities were spectrin and band 3 deficiencies in both nonsplenectomized and splenectomized patients. The membrane protein defect was undetectable in 9
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RESULTS
(7%) non-splenectomized subjects, seven of whom had a positive family history of HS; the remaining two displayed mild anemia, reticulocytosis and 5% spherocytes, in the absence of other causes of chronic hemolytic anemia. Table 2 compares the sensitivity of the diagnostic laboratory tests for HS. EMA-binding failed to identify 10/150 (7%) cases (4 band 3 deficiency, 5 spectrin deficiency and 1 "undetected"). The mean decrease in fluorescence was 27% ± 10% in HS vs 0 % ± 8% in reference subjects (P<0.001).
The percent fluorescence reduction was directly related to the spherocyte number and indirectly with MCV; no correlation was found with either hemoglobin, reticulocyte absolute number and red cell distribution width (RDW). The test's sensitivity was independent of the type and amount of molecular defect, although it was slightly lower in "undetected" patients that displayed the mildest median decrease in fluorescence (15% vs 30% and 28% in band 3 and spectrin deficiency respectively). It is worth noting that the EMA-binding test sensitivity was slightly higher in splenectomized than in non-splenectomized patients (Figure 1 ).
The sensitivity of the various red cell fragility assays investigated was greatly variable, and generally higher in splenectomized than in non-splenectomized HS, and lower (with the exception of AGLT) in the undetected patients compared with those with detectable defects (Table 2A) . As regards the NaCl OF test, the sensitivity was greater when performed on incubated than on fresh blood. Overall, NaCl OF tests (both on fresh and incubated blood) had a lower sensitivity when compared with the more commonly used glycerol-based tests. Among these latter assays, AGLT displayed the highest sensitivity, also in the undetected cases, comparable to that of EMA-binding test.
All HS patients were positive to at least two different tests with the exception of two (one band 3 and one spectrin deficient cases) who were EMA-binding positive only. We found that the combination of EMA and AGLT enabled to identify the totality of HS patients (Table 2B) The results of various tests on a series of 84 patients with hemolytic conditions other than HS are depicted in Figure 2 . EMA-binding shows the greater disease specificity being negative in all patients with AIHA, even in the presence of marked spherocytosis.
DISCUSSION
This is the first extensive comparison study of the most currently used laboratory methods for diagnosing HS, carried out on a large number of patients grouped according to the molecular defect, the degree of hemolysis and the presence or absence of the spleen. The finding that half of the examined patients displayed mild/compensated anemia, and were therefore more difficult to diagnose, and that 18% had very few spherocytes on peripheral blood smear, makes the population examined particularly suitable for sensitivity studies. We didn't include in this study the cryohemolysis test, 17 since the basis of HS red cells susceptibility to cooling has not been so far elucidated, and opinions on its routine utilization for diagnosis of HS are controversial. 4, 5, 16, 17, 19, 37, 38 Among the diagnostic methods considered, the recently proposed EMA-binding test is certainly the most interesting one, and it is increasingly used by specialized laboratories for its high sensitivity and specificity. 12, 18, [23] [24] [25] [26] [27] [28] [29] Interestingly, sensitivity is independent of clinical phenotype, being high also in patients with compensated anemia. The separate analysis of non-splenectomized and splenectomized HS patients showed that sensitivity increased in the latter group, a finding generally common to all the tests investigated; this observation pinpoints to the need to precisely define the clinical characteristics of patients when testing the performance of diagnostic methods for HS, and possibly to limit the analysis to non-splenectomized subjects. A further advantage of EMA-binding test is that results are not influenced by shipping or storage up to 6 days as shown in Figure 3 , thus enabling shipping of samples as reported by Girodon et al. 25 Moreover, results are not affected by recent transfusions since the method discriminates different red cell populations.
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As regards the NaCl OF tests, we found that they miss nearly a quarter of HS patients, in agreement with what observed by others, 12, 13, 19, 40, 41 and that their sensitivity is generally lower than that of the other diagnostic laboratory tests evaluated in this series. The disease specificity of the diagnostic tests for HS has been evaluated by including in the study a large group of various hemolytic anemias that may show morphological and laboratory features similar to HS. As expected, the results of EMA-binding, in terms of percent fluorescence reduction, were directly related with the number of spherocytes in HS patients only, but not in AIHA, even in those with marked spherocytosis: this observation is in line with the high disease specificity of this test reported by others. [19] [20] [21] 25 We found that the other assays, in particular the glycerol-based ones, are less specific than EMA-binding, being often positive also in acquired hemolytic anemias, as previously reported. 8, 9, 14, 15, 46 It is worth mentioning that none of the available diagnostic tests for HS, neither direct or indirect, differentiates HS from CDAII. This latter, although less prevalent than HS, may mimics HS both in terms of clinical presentation, red cell morphology and increased red cell osmotic fragility, and may require SDS-PAGE analysis to be identified: Mariani et al reported that 13% of cases referred to a reference laboratory with the provisional label of HS were found to be CDAII when examined by SDS-PAGE. even the association of these two tests gives a sensitivity of 93%, similar to that of EMA binding or AGLT used alone, and much lower than that obtained by the combination EMA-binding/AGLT. 
As seen in
PAGE analysis to exclude CDAII. SDS-PAGE analysis may also be required in the rare
EMA-AGLT+ cases with negative family history, due to the less disease specificity of AGLT.
In conclusion no single test is able to identify all the HS cases. The association of EMA-binding, that directly targets the structural defect of HS, and AGLT, which exploit the red cell surface areato volume ratio, allowed to identify all the HS patients of this series and therefore represents a very effective diagnostic tool for HS also in mild/compensated cases. However, it must be underlined that the diagnosis of HS is the final step of a diagnostic workout based not only on laboratory test but also on clinical examination, personal family history, and the exclusion of possible causes of secondary spherocytosis.
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